Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats

被引:53
作者
Sogut, S
Ozyurt, H
Armutcu, F
Kart, L
Iraz, M
Akyol, O
Ozen, S
Kaplan, S
Temel, I
Yildirim, Z [1 ]
机构
[1] Inonu Univ, Fac Med, Turgut Ozal Med Ctr, Dept Pulm Med, TR-44069 Malatya, Turkey
[2] Mustafa Kemal Univ, Fac Med, Dept Biochem, Antakya, Turkey
[3] Gaziosmanpasa Univ, Fac Med, Dept Biochem, Tokat, Turkey
[4] Karalemas Univ, Fac Med, Dept Biochem, Zonguldak, Turkey
[5] Karalemas Univ, Fac Med, Dept Pulm Med, Zonguldak, Turkey
[6] Inonu Univ, Fac Med, Dept Pharmacol, Malatya, Turkey
[7] Inonu Univ, Fac Med, Dept Biochem, Malatya, Turkey
[8] Yuzuncu Yil Univ, Fac Med, Dept Pathol, Van, Turkey
[9] Ondokuz Mayis Univ, Fac Med, Dept Histol, TR-55139 Samsun, Turkey
关键词
erdosteine; bleomycin; lung fibrosis; myeloperoxidase; hydroxyproline;
D O I
10.1016/j.ejphar.2004.04.045
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oxidative stress plays an important role in the pathogenesis of idiopathic pulmonary fibrosis. Therefore, erdosteine, an antioxidant, is expected to have an inhibitor potential against the disease. Rats were given one dose of bleomycin in pulmonary fibrosis groups and saline in controls. The first dose of oral erdosteine (10 mg/kg/day) was given 2 days before the bleomycin injection to achieve the plateau level in blood and continued until killing. At day 14, fibrotic changes were evaluated, using Aschoft's criteria and lung hydroxyproline content. Bleomycin produced a fivefold increase in fibrosis score that was decreased by 87% by erdosteine (P>0.001) and almost twofold increases in hydroxyproline content which were completely prevented by erdosteine. Myeloperoxidase activities and MDA levels, which were significantly higher in the bleomycin group, were then significantly attenuated by erdosteine. These results revealed that oral erdosteine may prevent the development of acute pulmonary inflammation caused by bleomycin injection via the repression of neutrophil accumulation and lipid peroxidation, resulting in the inhibition of subsequent lung fibrosis. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:213 / 220
页数:8
相关论文
共 31 条
[1]  
[Anonymous], 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00
[2]   SIMPLE METHOD OF ESTIMATING SEVERITY OF PULMONARY FIBROSIS ON A NUMERICAL SCALE [J].
ASHCROFT, T ;
SIMPSON, JM ;
TIMBRELL, V .
JOURNAL OF CLINICAL PATHOLOGY, 1988, 41 (04) :467-470
[3]   Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis - Adjunctive therapy to maintenance immunosuppression [J].
Behr, J ;
Maier, K ;
Degenkolb, B ;
Krombach, F ;
Vogelmeier, C .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (06) :1897-1901
[4]   PATHOGENETIC SIGNIFICANCE OF REACTIVE OXYGEN SPECIES IN DIFFUSE FIBROSING ALVEOLITIS [J].
BEHR, J ;
MAIER, K ;
KROMBACH, F ;
ADELMANNGRILL, BC .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1991, 144 (01) :146-150
[5]   EFFECT OF GLUTATHIONE AEROSOL ON OXIDANT-ANTIOXIDANT IMBALANCE IN IDIOPATHIC PULMONARY FIBROSIS [J].
BOROK, Z ;
BUHL, R ;
GRIMES, GJ ;
BOKSER, AD ;
HUBBARD, RC ;
HOLROYD, KJ ;
ROUM, JH ;
CZERSKI, DB ;
CANTIN, AM ;
CRYSTAL, RG .
LANCET, 1991, 338 (8761) :215-216
[6]   Role of extracellular superoxide dismutase in bleomycin-induced pulmonary fibrosis [J].
Bowler, RP ;
Nicks, M ;
Warnick, K ;
Crapo, JD .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2002, 282 (04) :L719-L726
[7]  
Braga PC, 2000, ARZNEIMITTELFORSCH, V50, P739
[8]   Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats [J].
Cortijo, J ;
Cerdá-Nicolás, M ;
Serrano, A ;
Bioque, G ;
Estrela, JM ;
Santangelo, F ;
Esteras, A ;
Llombart-Bosch, A ;
Morcillo, EJ .
EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (06) :1228-1235
[9]   Erdosteine [J].
Dechant, KL ;
Noble, S .
DRUGS, 1996, 52 (06) :875-881
[10]   Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats [J].
Fadillioglu, E ;
Erdogan, H ;
Sögüt, S ;
Kuku, I .
JOURNAL OF APPLIED TOXICOLOGY, 2003, 23 (01) :71-74